CN107812014B - 自体真皮成纤维细胞的剂量单位调配物 - Google Patents
自体真皮成纤维细胞的剂量单位调配物 Download PDFInfo
- Publication number
- CN107812014B CN107812014B CN201710907274.2A CN201710907274A CN107812014B CN 107812014 B CN107812014 B CN 107812014B CN 201710907274 A CN201710907274 A CN 201710907274A CN 107812014 B CN107812014 B CN 107812014B
- Authority
- CN
- China
- Prior art keywords
- cells
- fibroblasts
- dosage formulation
- treatment
- dyes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 155
- 239000000203 mixture Substances 0.000 title claims description 82
- 238000009472 formulation Methods 0.000 title claims description 68
- 230000002500 effect on skin Effects 0.000 title description 14
- 210000004027 cell Anatomy 0.000 claims abstract description 247
- 238000000034 method Methods 0.000 claims abstract description 43
- 230000037303 wrinkles Effects 0.000 claims abstract description 41
- 238000011282 treatment Methods 0.000 claims description 91
- 231100000241 scar Toxicity 0.000 claims description 47
- 239000000975 dye Substances 0.000 claims description 42
- 210000003491 skin Anatomy 0.000 claims description 33
- 241000508269 Psidium Species 0.000 claims description 21
- 230000001815 facial effect Effects 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 16
- 210000004207 dermis Anatomy 0.000 claims description 15
- 210000002510 keratinocyte Anatomy 0.000 claims description 15
- 206010039580 Scar Diseases 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000007547 defect Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000009826 distribution Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000012595 freezing medium Substances 0.000 claims description 7
- 230000002045 lasting effect Effects 0.000 claims description 6
- 230000017423 tissue regeneration Effects 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 5
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 claims description 3
- 230000007910 cell fusion Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 210000001082 somatic cell Anatomy 0.000 claims description 2
- MPBRYMWMMKKRGC-UHFFFAOYSA-M carbocyanin DBTC Chemical compound [Br-].C1=CC=CC2=C([N+](=C(C=C(C)C=C3N(C4=C5C=CC=CC5=CC=C4S3)CC)S3)CC)C3=CC=C21 MPBRYMWMMKKRGC-UHFFFAOYSA-M 0.000 claims 7
- 206010040954 Skin wrinkling Diseases 0.000 claims 3
- 239000000725 suspension Substances 0.000 abstract description 30
- 210000001519 tissue Anatomy 0.000 abstract description 17
- 230000035899 viability Effects 0.000 abstract description 16
- 108010035532 Collagen Proteins 0.000 abstract description 14
- 102000008186 Collagen Human genes 0.000 abstract description 14
- 238000001574 biopsy Methods 0.000 abstract description 14
- 229920001436 collagen Polymers 0.000 abstract description 14
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract description 6
- 238000011018 current good manufacturing practice Methods 0.000 abstract description 5
- 210000002744 extracellular matrix Anatomy 0.000 abstract description 5
- 239000002243 precursor Substances 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 238000011130 autologous cell therapy Methods 0.000 abstract description 3
- 238000002347 injection Methods 0.000 description 48
- 239000007924 injection Substances 0.000 description 48
- 239000000523 sample Substances 0.000 description 29
- 239000001963 growth medium Substances 0.000 description 25
- 239000000902 placebo Substances 0.000 description 24
- 229940068196 placebo Drugs 0.000 description 24
- 239000012071 phase Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 208000032544 Cicatrix Diseases 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 230000006872 improvement Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 230000037387 scars Effects 0.000 description 17
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 239000006285 cell suspension Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 206010052428 Wound Diseases 0.000 description 12
- 238000003260 vortexing Methods 0.000 description 12
- 208000002874 Acne Vulgaris Diseases 0.000 description 11
- 206010000496 acne Diseases 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 10
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 229940088679 drug related substance Drugs 0.000 description 8
- 238000002316 cosmetic surgery Methods 0.000 description 7
- 238000007710 freezing Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940055553 azficel-t Drugs 0.000 description 5
- 238000002659 cell therapy Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 101150067055 minC gene Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000001969 hypertrophic effect Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 238000002278 reconstructive surgery Methods 0.000 description 4
- 230000008672 reprogramming Effects 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010023330 Keloid scar Diseases 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 230000001973 epigenetic effect Effects 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010061619 Deformity Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010052014 Liberase Proteins 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101150052863 THY1 gene Proteins 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 238000011166 aliquoting Methods 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 239000012512 bulk drug substance Substances 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920002959 polymer blend Polymers 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 210000001260 vocal cord Anatomy 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000009899 Agrostemma githago Nutrition 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100032816 Integrin alpha-6 Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 102000000426 Integrin alpha6 Human genes 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 244000178320 Vaccaria pyramidata Species 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- POFWRMVFWIJXHP-UHFFFAOYSA-N n-benzyl-9-(oxan-2-yl)purin-6-amine Chemical compound C=1C=CC=CC=1CNC(C=1N=C2)=NC=NC=1N2C1CCCCO1 POFWRMVFWIJXHP-UHFFFAOYSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000010909 process residue Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000037339 smooth wrinkles Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000011856 somatic therapy Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/776,163 US8529883B2 (en) | 2010-05-07 | 2010-05-07 | Dosage unit formulations of autologous dermal fibroblasts |
| US12/776,163 | 2010-05-07 | ||
| CN2011800230385A CN102905711A (zh) | 2010-05-07 | 2011-05-05 | 自体真皮成纤维细胞的剂量单位调配物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800230385A Division CN102905711A (zh) | 2010-05-07 | 2011-05-05 | 自体真皮成纤维细胞的剂量单位调配物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107812014A CN107812014A (zh) | 2018-03-20 |
| CN107812014B true CN107812014B (zh) | 2021-11-16 |
Family
ID=44121161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710907274.2A Active CN107812014B (zh) | 2010-05-07 | 2011-05-05 | 自体真皮成纤维细胞的剂量单位调配物 |
| CN2011800230385A Pending CN102905711A (zh) | 2010-05-07 | 2011-05-05 | 自体真皮成纤维细胞的剂量单位调配物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800230385A Pending CN102905711A (zh) | 2010-05-07 | 2011-05-05 | 自体真皮成纤维细胞的剂量单位调配物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8529883B2 (https=) |
| EP (1) | EP2566489B1 (https=) |
| JP (1) | JP6309268B2 (https=) |
| KR (1) | KR102001254B1 (https=) |
| CN (2) | CN107812014B (https=) |
| AU (1) | AU2011248067B2 (https=) |
| CA (1) | CA2800333C (https=) |
| WO (1) | WO2011140323A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8728819B2 (en) | 2006-08-29 | 2014-05-20 | Fibrocell Technologies, Inc. | Methods for culturing minimally-passaged fibroblasts and uses thereof |
| US8512715B2 (en) * | 2008-08-14 | 2013-08-20 | The Cleveland Clinic Foundation | Apparatus and method for treating a neuromuscular defect |
| WO2011075676A2 (en) | 2009-12-18 | 2011-06-23 | Knowlton Edward W | A skin treatment and drug delivery device |
| US8529883B2 (en) * | 2010-05-07 | 2013-09-10 | Fibrocell Technologies, Inc. | Dosage unit formulations of autologous dermal fibroblasts |
| US8765121B2 (en) | 2010-10-14 | 2014-07-01 | Fibrocell Technologies, Inc. | Treatment of vocal cords with autologous dermal fibroblast formulation |
| US11109887B2 (en) | 2013-12-06 | 2021-09-07 | Srgi Holdings, Llc | Pixel array medical systems, devices and methods |
| US11278309B2 (en) | 2010-12-17 | 2022-03-22 | Srgi Holdings, Llc | Pixel array medical systems, devices and methods |
| US10080581B2 (en) | 2010-12-17 | 2018-09-25 | Srgi Holding Llc | Pixel array medical devices and methods |
| US10695546B2 (en) | 2010-12-17 | 2020-06-30 | Srgi Holdings, Llc | Systems, devices and methods for fractional resection, fractional skin grafting, fractional scar reduction and fractional tattoo removal |
| US10736653B2 (en) | 2013-12-06 | 2020-08-11 | Srgi Holdings, Llc | Pixel array medical systems, devices and methods |
| US11000310B2 (en) | 2010-12-17 | 2021-05-11 | Srgi Holdings, Llc | Pixel array medical systems, devices and methods |
| US10967162B2 (en) | 2010-12-17 | 2021-04-06 | Srgi Holdings, Llc | Systems, devices and methods for fractional resection, fractional skin grafting, fractional scar reduction and fractional tattoo removal |
| US11103275B2 (en) | 2010-12-17 | 2021-08-31 | Srgi Holdings, Llc | Pixel array medical systems, devices and methods |
| US10702684B2 (en) | 2010-12-17 | 2020-07-07 | Srgi Holdings, Llc | Systems, devices and methods for fractional resection, fractional skin grafting, fractional scar reduction and fractional tattoo removal |
| HK1205707A1 (en) * | 2012-03-07 | 2015-12-24 | Fibrocell Technologies, Inc. | Topical dermal formulations and methods of personalized treatment of skin |
| EP2836591B1 (en) | 2012-04-09 | 2018-06-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for generation of pluripotent and multipotent cells |
| WO2014039995A1 (en) * | 2012-09-07 | 2014-03-13 | Fibrocell Technologies, Inc. | Fibroblast compositions for treating cardial damage after an infarct |
| ITMI20131053A1 (it) * | 2013-06-25 | 2014-12-26 | Maria Oliva Salviati | Composizione che comprende ortica |
| ES2827049T3 (es) | 2013-10-02 | 2021-05-19 | Srgi Holdings Llc | Dispositivos médicos de conjunto de píxeles |
| US11229452B2 (en) | 2013-12-06 | 2022-01-25 | Srgi Holdings, Llc | Pixel array medical systems, devices and methods |
| US11937846B2 (en) | 2013-12-06 | 2024-03-26 | Srgi Holdings Llc | Pixel array medical systems, devices and methods |
| EP3579767B1 (en) | 2014-10-02 | 2025-10-08 | SRGI Holdings, LLC | Pixel array medical systems and devices |
| WO2016127091A1 (en) | 2015-02-05 | 2016-08-11 | Srgi Holdings, Llc | Pixel array medical systems, devices and methods |
| US11980389B2 (en) | 2015-08-31 | 2024-05-14 | Srgi Holdings Llc | Handed spiral slotted scalpet array |
| US11490952B2 (en) | 2015-08-31 | 2022-11-08 | Srgi Holdings, Llc | Pixel array medical devices and methods |
| US11751904B2 (en) | 2015-08-31 | 2023-09-12 | Srgi Holdings, Llc | Pixel array medical systems, devices and methods |
| US12551509B2 (en) | 2015-11-18 | 2026-02-17 | Lucina Patent Holdco, Llc | Acellular regenerative products and methods of their manufacture |
| WO2017100425A1 (en) * | 2015-12-10 | 2017-06-15 | Aesthetics Biomedical, Inc. | Topical formulation for skin care |
| US11564706B2 (en) | 2019-10-28 | 2023-01-31 | Srgi Holdings, Llc | Pixel array medical systems, devices and methods |
| GB201818243D0 (en) * | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| WO2020223148A1 (en) * | 2019-04-27 | 2020-11-05 | Figene, Llc | Enhancement of fibroblast therapeutic activity by t cell modulation |
| US12544407B2 (en) | 2019-04-28 | 2026-02-10 | Fibrobiologics, Inc. | Fibroblast cell therapy for treatment of osteoporosis |
| CN110075125A (zh) * | 2019-05-10 | 2019-08-02 | 成都康景生物科技有限公司 | 一种用于治疗系统性硬化症伴随肢端硬化的脐带间充质干细胞注射液及其制备方法 |
| EP4061923A4 (en) * | 2019-11-22 | 2024-01-03 | Cutiss AG | Methods and systems for producing skin grafts |
| AU2021245671A1 (en) * | 2020-03-31 | 2022-10-20 | Cell Exosome Therapeutics Inc. | Cell preservation method |
| KR20220074132A (ko) | 2020-11-27 | 2022-06-03 | 테고사이언스 (주) | 건 재생 효과를 나타내는 피부 유래 섬유아세포 및 이의 용도 |
| WO2023178219A1 (en) * | 2022-03-16 | 2023-09-21 | Fibrobiologics, Inc. | Therapeutic use of fibroblasts for use in wound healing |
| JP2023150483A (ja) * | 2022-03-31 | 2023-10-16 | ポーラ化成工業株式会社 | コラーゲン代謝促進剤、及びコラーゲン代謝に関与する細胞群を特定する方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4524065A (en) | 1983-08-04 | 1985-06-18 | Bio-Specifics N.V. | Method for the prevention and treatment of scars with enzymes |
| US4772557A (en) | 1985-11-12 | 1988-09-20 | Washington University | DNA clone of human skin fibroblast collagenase enzyme |
| US5591444A (en) | 1995-07-28 | 1997-01-07 | Isolagen Technologies, Inc. | Use of autologous dermal fibroblasts for the repair of skin and soft tissue defects |
| US20040229203A1 (en) * | 1996-06-14 | 2004-11-18 | Biostore New Zealand Ltd. | Compositions and methods for the preservation of living tissues |
| AU6662698A (en) | 1997-02-20 | 1998-09-09 | Gregory S. Keller | Augmentation and repair of dermal, subcutaneous, and vocal cord tissue defects |
| US7767452B2 (en) | 1997-02-20 | 2010-08-03 | Kleinsek Don A | Tissue treatments with adipocyte cells |
| US6110459A (en) | 1997-05-28 | 2000-08-29 | Mickle; Donald A. G. | Transplants for myocardial scars and methods and cellular preparations |
| US6150505A (en) * | 1997-09-19 | 2000-11-21 | Hadasit Medical Research Services & Development Ltd. | Fibrin microbeads prepared from fibrinogen, thrombin and factor XIII |
| US7115417B1 (en) * | 1998-05-01 | 2006-10-03 | Chancellor Michael B | Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof |
| US6432710B1 (en) | 1998-05-22 | 2002-08-13 | Isolagen Technologies, Inc. | Compositions for regenerating tissue that has deteriorated, and methods for using such compositions |
| WO2000073418A2 (en) | 1999-05-28 | 2000-12-07 | Pacgen Technologies Llc | A method of using autologous fibroblasts to promote healing of wounds and fistulas |
| US6733530B1 (en) | 1999-08-02 | 2004-05-11 | Eric Sun-Yin Chan | Material and method for engraftment of a composite biocompatible skin graft on the neodermis of artificial skin |
| US20080286242A2 (en) | 1999-11-05 | 2008-11-20 | Donald Kleinsek | Augmentation and repair of spincter defects with cells including mesenchymal cells |
| US7799325B2 (en) | 1999-11-05 | 2010-09-21 | Kleinsek Donald A | Removal of hypertrophic scars |
| US20040101959A1 (en) | 2002-11-21 | 2004-05-27 | Olga Marko | Treatment of tissue with undifferentiated mesenchymal cells |
| US7186557B2 (en) | 2003-06-13 | 2007-03-06 | Isolagen Technologies, Inc. | Methods of producing neurons |
| WO2005001080A2 (en) | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system |
| JP2007520259A (ja) * | 2003-11-10 | 2007-07-26 | シンフォニー メディカル， インコーポレイテッド | 心房細動患者における心室速度を制御するための方法 |
| AU2006251004C1 (en) * | 2005-05-26 | 2013-05-23 | Intercytex Limited | Tissue repair using allogenic dermal fibroblasts |
| KR20080087148A (ko) * | 2006-01-04 | 2008-09-30 | 두-쿱 테크놀로지스 리미티드 | 저온보호 조성물 및 그 이용방법 |
| US20070264239A1 (en) * | 2006-05-10 | 2007-11-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Isolation of pericytes |
| GB2440908A (en) * | 2006-05-25 | 2008-02-20 | Intercytex Ltd | Tissue Repair and Augmentation |
| US20070298005A1 (en) * | 2006-06-22 | 2007-12-27 | Marie-Josee Thibault | Injectable composition for treatment of skin defects or deformations |
| KR20070122316A (ko) | 2006-06-26 | 2007-12-31 | (주) 에스바이오메딕스 | 주사용 인체 연조직 충전제 및 이의 제조 방법 |
| WO2008008827A2 (en) * | 2006-07-13 | 2008-01-17 | Medtronic, Inc. | Methods and formulations for optimal local delivery of cell therapy via minimally invasive procedures |
| US8728819B2 (en) * | 2006-08-29 | 2014-05-20 | Fibrocell Technologies, Inc. | Methods for culturing minimally-passaged fibroblasts and uses thereof |
| JP4247333B2 (ja) * | 2006-12-28 | 2009-04-02 | 国立大学法人名古屋大学 | 皮膚組織改善材およびその製造方法 |
| US20100303770A1 (en) | 2006-12-28 | 2010-12-02 | John Maslowski | Methods for culturing dermal cells for treatment of skin injuries such as burns |
| JP2008245583A (ja) * | 2007-03-30 | 2008-10-16 | Yamaguchi Univ | 哺乳動物の神経細胞の精製培養方法とその保存方法 |
| US7960098B2 (en) * | 2007-07-12 | 2011-06-14 | Warsaw Orthoperic, Inc. | Methods and compositions for the preservation of cells and tissues |
| EP2190976A4 (en) | 2007-08-10 | 2010-10-20 | Univ Dayton | METHOD FOR PRODUCING PLURIPOTENTAL STEM CELL LENGTH CELLS |
| JP2009148236A (ja) * | 2007-12-20 | 2009-07-09 | Glycoresearch Kk | 線維芽細胞の細胞識別方法 |
| US20090209456A1 (en) * | 2008-02-19 | 2009-08-20 | Iliana Sweis | Compositions and methods for improving facial and body aesthetics |
| WO2009142717A2 (en) * | 2008-05-19 | 2009-11-26 | President And Fellows Of Harvard College | Methods and products for dedifferentiation of cells |
| US8669048B2 (en) * | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
| CN102186969A (zh) * | 2008-06-25 | 2011-09-14 | 国家健康与医学研究院 | 由人多能干细胞制备人皮肤替代品的方法 |
| JP2012518409A (ja) * | 2009-02-20 | 2012-08-16 | ベントリア・バイオサイエンス | タンパク質の組み合わせを含有する細胞培養培地 |
| US8240314B2 (en) * | 2009-04-06 | 2012-08-14 | Eden Esthetics, A Professional Nursing Corporation | Method for injecting fillers into the dermis |
| JP5816416B2 (ja) * | 2010-04-23 | 2015-11-18 | 国立大学法人名古屋大学 | 細胞評価装置、インキュベータ、プログラム、および、培養方法 |
| US8529883B2 (en) * | 2010-05-07 | 2013-09-10 | Fibrocell Technologies, Inc. | Dosage unit formulations of autologous dermal fibroblasts |
-
2010
- 2010-05-07 US US12/776,163 patent/US8529883B2/en active Active
-
2011
- 2011-05-05 AU AU2011248067A patent/AU2011248067B2/en active Active
- 2011-05-05 WO PCT/US2011/035332 patent/WO2011140323A1/en not_active Ceased
- 2011-05-05 CN CN201710907274.2A patent/CN107812014B/zh active Active
- 2011-05-05 KR KR1020127030921A patent/KR102001254B1/ko active Active
- 2011-05-05 JP JP2013509258A patent/JP6309268B2/ja active Active
- 2011-05-05 EP EP11720666.4A patent/EP2566489B1/en active Active
- 2011-05-05 CN CN2011800230385A patent/CN102905711A/zh active Pending
- 2011-05-05 CA CA2800333A patent/CA2800333C/en active Active
-
2013
- 2013-07-12 US US13/941,265 patent/US11554142B2/en active Active
-
2022
- 2022-12-12 US US18/079,358 patent/US20230270793A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011248067A1 (en) | 2012-12-20 |
| KR102001254B1 (ko) | 2019-07-17 |
| CA2800333A1 (en) | 2011-11-10 |
| US20110274665A1 (en) | 2011-11-10 |
| CA2800333C (en) | 2018-10-30 |
| JP6309268B2 (ja) | 2018-04-11 |
| KR20130060212A (ko) | 2013-06-07 |
| US20130295061A1 (en) | 2013-11-07 |
| EP2566489A1 (en) | 2013-03-13 |
| EP2566489B1 (en) | 2019-04-24 |
| US20230270793A1 (en) | 2023-08-31 |
| US11554142B2 (en) | 2023-01-17 |
| WO2011140323A1 (en) | 2011-11-10 |
| AU2011248067B2 (en) | 2015-03-12 |
| CN107812014A (zh) | 2018-03-20 |
| US8529883B2 (en) | 2013-09-10 |
| JP2013524856A (ja) | 2013-06-20 |
| CN102905711A (zh) | 2013-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107812014B (zh) | 自体真皮成纤维细胞的剂量单位调配物 | |
| US10881695B2 (en) | Treatment of vocal cords with autologous dermal fibroblast formulation | |
| JP7386162B2 (ja) | 線維芽細胞の再生活性の増強 | |
| Supp et al. | Isolation and feeder-free primary culture of four cell types from a single human skin sample | |
| CN102625689A (zh) | 用于恢复面部或身体所选区域中年龄相关组织损失的方法和组合物 | |
| EP3579844A2 (en) | Biological scaffolds, products containing biological scaffolds and methods of using the same | |
| JP2022069524A (ja) | 改良された細胞療法 | |
| CN108057116A (zh) | 干细胞组合物在皮肤损伤治疗药物中的应用 | |
| JP4247333B2 (ja) | 皮膚組織改善材およびその製造方法 | |
| CN108066750A (zh) | 干细胞及其分泌物用于治疗皮肤烧烫伤的新用途 | |
| CN115404203A (zh) | 毛囊间充质干细胞的制备方法以及应用 | |
| Tsimponis et al. | The effect of host tissue and radiation on fat-graft survival: A comparative experimental study | |
| HK1180968A (en) | Dosage unit formulations of autologous dermal fibroblasts | |
| CN108066824A (zh) | 一种制备表皮缺损治疗药物的新方法 | |
| CN108057131A (zh) | 一种含有干细胞的新型试剂盒 | |
| US20240293471A1 (en) | Placental cell treatment for critical limb ischemia patient subpopulations | |
| Martins et al. | Adipose tissue mature stem cells in skin healing: a controlled randomized study | |
| Manturova et al. | Treatment of Skin Wounds in Old Animals Using Mesenzymal Progenitor Cells and Polymer Gel Compositions | |
| Boon | Expansion of Skin-Derived Precursor Cells (SKPs) in Stirred Suspension Bioreactors | |
| 大串始 | Development of regenerative medical technology working toward practical application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210429 Address after: Pennsylvania, USA Applicant after: Farbrossel science Inc. Address before: Pennsylvania, USA Applicant before: Fibrocell Technologies, Inc. Effective date of registration: 20210429 Address after: Pennsylvania, USA Applicant after: Caserkrick bioscience Co.,Ltd. Address before: Pennsylvania, USA Applicant before: Farbrossel science Inc. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |